Frequency of Covid-19 Infection and The Disease Profile in Patients Followed with Multiple Sclerosis

Yıl 2024, Cilt: 19 Sayı: 1, 56 - 62, 28.03.2024

Yusuf Ziya Deniz , Mehmet Tecellioğlu , Cemal Özcan

https://doi.org/10.17517/ksutfd.1191897

Öz

Objective: For a long time immunomodulatory / immunosuppressive drugs have been used to slow the progression of multiple sclerosis (MS). These treatments are known to suppress the immune system and create susceptibility to infections. In our study, it was aimed to review the severity and frequency of COVID-19 disease in MS patients who received immunomodulatory/immunosuppressive treatments during the current coronavirus disease 2019 (COVID-19) pandemic, and also to evaluate whether they were adversely affected in terms of psychological outcomes.

Material and Methods: Participants consisted of MS patients who acquired COVID-19 (group 1) aged 18-65, using disease-modifying treatments (DMT) with follow-up in a neurology outpatient the clinic and the other two control groups consisted of similar ages and genders.
One of the other two groups is MS patients who have not had COVID-19 (group 2), the other group consisted of patients who had COVID-19 and did not have MS (group 3). MS profile, coronavirus anxiety scale (CAS), and Beck depression inventory (BDI) scales between groups 1 and 2; COVID-19 profile between groups 1 and 3 compared.

Results: As a result of comparing the MS disease profile of the 1st and 2nd groups and in terms of the COVID-19 disease profile of the 1st and 3rd groups, there was no statistically
a significant difference in these paired comparison groups (p> 0.05).

Conclusions: It was concluded that DMT use does not increase the severity of COVID-19 and having COVID-19 does not cause any additional changes in the psychiatric status of MS patients, since no a statistically significant difference was observed in the 2 MS group and 2 COVID-19 group comparison.

Anahtar Kelimeler

multiple sclerosis, infection, COVID-19, disease modifying treatment

Multipl Skleroz Tanısı ile Takip Edilen Hastalarda Covid-19 Enfeksiyonu Geçirme Sıklığı ve Hastalık Profili

Öz

Amaç: Multipl skleroz hastalığının (MS) ilerlemesini yavaşlatmak için uzun süredir immünomodülatör / immünsüpresif ilaçlar kullanılmaktadır. Bu tedavilerin bağışıklık sistemini baskıladığı ve enfeksiyonlara yatkınlık oluşturduğu bilinmektedir. Çalışmamızda mevcut koronavirüs (COVID-19) pandemisinde immünomodülatör/immünosupresif tedaviler alan MS hastalarının COVID-19 hastalık şiddeti ve sıklığının gözden geçirilmesi ve ayrıca psikolojik sonuçları açısından olumsuz etkilenip etkilenmediklerinin değerlendirilmesi amaçlanmıştır.
Gereç ve Yöntemler: Katılımcılar, nöroloji polikliniğinde takipli hastalık modifiye edici tedaviler (DMT) kullanan 18-65 yaş aralığında COVID-19 geçirmiş MS hastalarından (grup 1) ve benzer yaş ve cinsiyete sahip 2 farklı kontrol grubundan oluşmaktaydı. Diğer iki gruptan biri COVID-19 geçirmeyen MS hastaları (grup 2), diğeri ise COVID-19 geçiren ve MS olmayan hastalardan oluşuyordu (grup 3). Grup 1 ve 2 arasında MS profili, koronavirüs anksiyete ölçeği (CAS) ve Beck depresyon envanteri (BDI) ölçekleri; Grup 1 ve 3 arasında ise COVID-19 hastalık profili karşılaştırıldı.
Bulgular: 1. ve 2. grubun MS hastalık profili ile 1. ve 3. grubun COVID-19 hastalık profili açısından karşılaştırılması sonucunda bu ikili karşılaştırma gruplarında istatistiksel olarak anlamlı bir fark bulunamadı (p> 0.05) .
Sonuç: 2 MS grubu ve 2 COVID-19 geçiren grup karşılaştırıldığında istatistiksel olarak anlamlı bir fark görülmediği için DMT kullanımının MS hastalarında COVID-19 hastalık şiddetini artırmadığı ve COVID-19 geçirmenin MS hastalarının psikiyatrik durumlarında ekstra bir değişikliğe yol açmadığı sonucuna varılmıştır.

Anahtar Kelimeler

multipl skleroz, enfeksiyon, COVID-19, hastalık modifiye edici tedavi

Kaynakça

• Gholamzad M, Ebtekar M, Ardestani MS, Azimi M, Mahmodi Z, Mousavi MJ, et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res. 2019 Jan;68(1):25-38.
• Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis. 2018 Jul 16;5(8):ofy174.
• Williamson EML, Berger JR. Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies. Neurotherapeutics. 2017 Oct;14(4):961-973.
• Grebenciucova E, Pruitt A. Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies. Curr Neurol Neurosci Rep. 2017 Sep 22;17(11):88.
• Loonstra FC, Hoitsma E, van Kempen ZL, Killestein J, Mostert JP. COVID-19 in multiple sclerosis: The Dutch experience. Mult Scler. 2020 Sep;26(10):1256-1260.
• Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, et al. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. J Chin Med Assoc. 2020 Sep;83(9):817-821.
• Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17(2):162-73.
• Thakolwiboon S, Zhao-Fleming H, Pan J, Scott JK, Shoji E, Sohn G, et al. Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of International and National Recommendations. Int J MS Care. 2020;22(4):151-157.
• CDC. COVID-19 symptom list. https://www.cdc.gov/coronavirus/2019-ncov/symptoms- testing/symptoms.html. Accessed at 12.10.2020
• Bsteh G, Bitschnau C, Hegen H, Auer M, Di Pauli F, Rommer P, et al. Multiple sclerosis and COVID-19: how many are at risk? Eur J Neurol. 2020 Sep 25:10.1111/ene.14555.
• Lee SA. Coronavirus Anxiety Scale: A brief mental health screener for COVID-19 related anxiety. Death Stud. 2020;44(7):393-401.
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun; 4:561-71.
• Fischer A, Fischer M, Nicholls RA, Lau S, Poettgen J, Patas K, et al. Diagnostic accuracy for major depression in multiple sclerosis using self-report questionnaires. Brain Behav 2015, 5(9):e00365.
• Covid19saglik.gov.tr. https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html. Accessed at 30.09.2020
• Ayache SS, Chalah MA. Fatigue in multiple sclerosis - Insights into evaluation and management. Neurophysiol Clin. 2017 Apr;47(2):139-171.
• Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):e835.
• Moreno-Torres I, Meca Lallana V, Costa-Frossard L, Oreja-Guevara C, Aguirre C, Alba Suárez EM, et al. Risk and outcomes of COVID-19 in patients with multiple sclerosis. Eur J Neurol. 2021 Nov;28(11):3712-3721.
• Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-583.
• Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020 Jun 27:10.1002/jmv.26232.
• Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, et al. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4):e753.
• Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult Scler Relat Disord. 2020 Jul; 42:102180.
• Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, et al. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. J Chin Med Assoc. 2020 Sep;83(9):817-821.
• Lee SA, Mathis AA, Jobe MC, Pappalardo EA. Clinically significant fear and anxiety of COVID-19: A psychometric examination of the Coronavirus Anxiety Scale. Psychiatry Res. 2020;290:113112.
• Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017 Jan 15;372:331-341.